TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss
The biotech firm increased its 2026 total global revenue target to around $950 million, up from $925 million previously. TG Therapeutics raised its U.S. Briumvi net product revenue guidance to $890 million-$905 million, compared with its prior outlook of $885 million-$900 million. TG reported Q2 total global revenue of $240.3 million, up 70% and also … Read more